

**Suppl. table 2. Clinical characteristics in patients with low and high****Ed/Ea before discharge and at 1 year after discharge:****cutoff point of Ed/Ea for all-cause mortality and/or****re-admission for heart failure**

	Ed/Ea: Before discharge		p-value (low vs. high)	Ed/Ea: 1 Year after		p-value (low vs. high)
	low ( $\leq 0.097$ )	high ( $> 0.097$ )		low ( $\leq 0.097$ )	high ( $> 0.097$ )	
	n = 216	n = 443		n = 116	n = 171	
All-cause mortality and/or hospitalization of heart failure, n (%)	38 (18)	144 (33)	<0.001	12 (10)	31 (18)	0.050
Age, years	79 ± 9	82 ± 9	<0.001	78 ± 11	81 ± 8	<0.001
Male sex, n (%)	124 (57)	172 (39)	<0.001	67 (58)	67 (39)	0.001
Systolic blood pressure, mmHg	123 ± 19	120 ± 19	0.051	131 ± 17	127 ± 20	0.077
Diastolic blood pressure, mmHg	67 ± 12	64 ± 12	0.004	72 ± 13	66 ± 12	<0.001
Heart rate, bpm	69 ± 15	70 ± 15	0.561	77 ± 13	65 ± 16	0.407
Atrial fibrillation, n (%)	99 (46)	191 (43)	0.509	55 (47)	74 (43)	0.284

<b>Coronary artery disease, n (%)</b>	<b>32 (15)</b>	<b>90 (20)</b>	<b>0.054</b>	<b>12 (10)</b>	<b>37 (22)</b>	<b>0.009</b>
<b>Diabetes mellitus, n (%)</b>	<b>74 (34)</b>	<b>159 (36)</b>	<b>0.372</b>	<b>37 (32)</b>	<b>65 (38)</b>	<b>0.174</b>
<b>Dyslipidemia, n (%)</b>	<b>88 (41)</b>	<b>182 (41)</b>	<b>0.500</b>	<b>46 (40)</b>	<b>79 (46)</b>	<b>0.164</b>
<b>Hypertension, n (%)</b>	<b>176 (81)</b>	<b>389 (88)</b>	<b>0.019</b>	<b>99 (85)</b>	<b>151 (88)</b>	<b>0.289</b>
<b>Laboratory data</b>						
Albumin, g/dL	<b>3.4 ± 0.4</b>	<b>3.4 ± 0.5</b>	<b>0.845</b>	<b>4.0 ± 0.4</b>	<b>3.9 ± 0.5</b>	<b>0.036</b>
eGFR, mL/min/1.73 m <sup>2</sup>	<b>46 ± 20</b>	<b>41 ± 19</b>	<b>0.004</b>	<b>48 ± 19</b>	<b>39 ± 19</b>	<b>&lt;0.001</b>
Hemoglobin, g/dL	<b>11.8 ± 2.0</b>	<b>11.2 ± 2.0</b>	<b>&lt;0.001</b>	<b>12.3 ± 1.6</b>	<b>11.6 ± 1.8</b>	<b>&lt;0.001</b>
NT-proBNP, pg/mL	<b>1948 ± 3877</b>	<b>2859 ± 6618</b>	<b>0.074</b>	<b>1524 ± 2534</b>	<b>2556 ± 4359</b>	<b>0.035</b>
<b>Echocardiographic data</b>						
LAD, mm	<b>43 ± 9</b>	<b>44 ± 8</b>	<b>0.032</b>	<b>43 ± 9</b>	<b>45 ± 8</b>	<b>0.054</b>
LAVI, mL/m <sup>2</sup>	<b>51 ± 26</b>	<b>55 ± 24</b>	<b>0.034</b>	<b>52 ± 29</b>	<b>52 ± 24</b>	<b>0.925</b>
SV/LAV	<b>0.76 ± 0.38</b>	<b>0.69 ± 0.34</b>	<b>0.021</b>	<b>0.72 ± 0.33</b>	<b>0.69 ± 0.35</b>	<b>0.553</b>
SV, mL	<b>50 ± 20</b>	<b>49 ± 20</b>	<b>0.416</b>	<b>48 ± 17</b>	<b>47 ± 13</b>	<b>0.819</b>

LVESV, mL	<b>36 ± 19</b>	<b>32 ± 16</b>	<b>0.008</b>	<b>30 ± 17</b>	<b>29 ± 13</b>	<b>0.472</b>
LVEDV, mL	<b>86 ± 36</b>	<b>80 ± 33</b>	<b>0.061</b>	<b>78 ± 30</b>	<b>76 ± 27</b>	<b>0.598</b>
LVEF, %	<b>60 ± 8</b>	<b>61 ± 8</b>	<b>0.018</b>	<b>62 ± 8</b>	<b>63 ± 8</b>	<b>0.592</b>
LVMI, g/m <sup>2</sup>	<b>104 ± 33</b>	<b>108 ± 34</b>	<b>0.160</b>	<b>97 ± 31</b>	<b>103 ± 30</b>	<b>0.109</b>
E, m/sec	<b>0.66 ± 0.20</b>	<b>0.93 ± 0.30</b>	<b>&lt;0.001</b>	<b>0.71 ± 0.19</b>	<b>0.95 ± 0.29</b>	<b>&lt;0.001</b>
mean e', cm/sec	<b>7.5 ± 2.3</b>	<b>6.0 ± 1.9</b>	<b>&lt;0.001</b>	<b>7.7 ± 1.8</b>	<b>5.9 ± 1.6</b>	<b>&lt;0.001</b>
DcT, sec	<b>0.20 ± 0.06</b>	<b>0.22 ± 0.07</b>	<b>0.026</b>	<b>0.23 ± 0.07</b>	<b>0.23 ± 0.08</b>	<b>0.944</b>
<b>Medications</b>						
Beta-blockers, %	<b>52</b>	<b>56</b>	<b>0.317</b>	<b>47</b>	<b>54</b>	<b>0.188</b>
Calcium-channel blockers, %	<b>50</b>	<b>53</b>	<b>0.607</b>	<b>47</b>	<b>51</b>	<b>0.471</b>
Diuretics, %	<b>84</b>	<b>83</b>	<b>0.759</b>	<b>74</b>	<b>80</b>	<b>0.224</b>
RAAS-I, %	<b>70</b>	<b>75</b>	<b>0.168</b>	<b>72</b>	<b>69</b>	<b>0.627</b>
Statins, %	<b>33</b>	<b>32</b>	<b>0.833</b>	<b>33</b>	<b>38</b>	<b>0.391</b>

All-cause mortality and/or re-admission for heart failure was evaluated for 2 years per year.

Values are mean ± standard deviation or number (%).

DcT, deceleration time of E wave;

Ed, diastolic elastance; Ea, arterial elastance; eGFR, estimated

**glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; LAD, left atrial diameter; LAVI, left atrial volume index; SV, stroke volume; LAV, left atrial volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVEDV, left ventricular end-diastolic volume; LVMI, left ventricular mass index; RAAS-I, renin-angiotensin-aldosterone system inhibitors**